Latest profit margin for Oryzon Genomics S.A.: -27.15% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Oryzon Genomics S.A. (ORY.MC) currently reports a profit margin of -27.15% as of June 2026. That compares with -36.07% in the prior-year period — up 24.7% year over year. That is below the Healthcare sector average of 17.63%. Use the charts on this page to explore Oryzon Genomics S.A.'s profit margin history and peer comparisons.
Oryzon Genomics S.A.'s profit margin increased from -36.07% to -27.15% — a 24.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Oryzon Genomics S.A.'s profit margin of -27.15% is lower than the Healthcare sector average of 17.63%. That is roughly 254.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Oryzon Genomics S.A.'s current -27.15% should be judged against Healthcare norms (sector average: 17.63%) and against ORY.MC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -27.15%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for Oryzon Genomics S.A., and consider following ORY.MC for alerts when major investors trade the stock.